Last updated: May 23, 2026
Folvite is the brand name for folic acid (vitamin B9) marketed for folate deficiency and related indications. Public clinical-trial activity for folic acid brands is limited in scope versus patented small-molecule drugs, and market dynamics are dominated by generic availability, low cost, and guideline-driven demand rather than drug-specific trial readouts.
Because “FOLVITE” is a brand-level label for a commodity active ingredient, the analysis below is organized around (1) clinical trial visibility for folic acid products and (2) market projection drivers tied to folate supplementation and fortification policy.
What clinical trials exist for FOLVITE (folic acid), and what is the latest update?
Are there phase 2/3 trials for FOLVITE specifically
No credible, consistently indexed phase 2/3 development program is publicly identifiable for “FOLVITE” as a standalone, brand-sponsored investigational drug. The clinical literature and trial registries typically treat folic acid as an active ingredient (vitamin) used in prevention and treatment contexts (dietary supplementation, anemia/hematology, pregnancy-related prophylaxis), with many studies conducted long before modern brand pharmacovigilance labeling and registries.
What trial areas keep recurring for folic acid products
Featured clinical use cases that repeatedly generate trial activity at the active-ingredient level include:
- Megaloblastic anemia / folate deficiency correction in adults and pediatrics
- Folate supplementation in pregnancy and periconceptional period to reduce neural tube defects
- Adjunctive regimens in oncology supportive care (context-dependent, often non-brand-specific)
- Cardiovascular and stroke risk markers studies through homocysteine lowering
- Genetic polymorphism stratification (for example, MTHFR variants) and pharmacodynamics
How to interpret “clinical trials updates” for FOLVITE
For commodity vitamins, “updates” typically reflect:
- Study publications and meta-analyses rather than late-stage registrational trials
- Safety and dosing confirmation studies in specific populations
- Policy-linked epidemiology (fortification and maternal supplementation compliance)
In practice, these do not translate into predictable, brand-level exclusivity expansion. Commercial outcomes track guideline adherence and payer formularies.
What is the market size and demand driver for folic acid products like FOLVITE?
Primary demand sources
- Pregnancy and periconception prevention
- Neural tube defect risk reduction strategies drive chronic baseline demand for folic acid supplements in many markets.
- Folate deficiency treatment
- Clinical management of malabsorption, nutritional deficiency, and selected hematologic conditions sustains use across adult and geriatric populations.
- Dietary fortification policy
- In countries with mandated fortification, the supplement market can be pressured on volume, but remains resilient because clinicians still recommend supplementation for high-risk groups and for pregnancy planning windows.
- Low-dose supportive use
- Hospitals and long-term care settings use tablets and generics as part of deficiency management protocols.
Pricing and competitive structure
Folic acid is typically sold as:
- Low-cost generics across many strengths (commonly 400 mcg, 1 mg, and higher)
- Multivitamin combinations (often with iron and B12)
- Brand labels exist but competition is usually determined by price and supply rather than patent protection.
When does FOLVITE lose exclusivity, and is there patent protection that affects generics?
Brand exclusivity
“FOLVITE” as a vitamin brand is generally not associated with new regulatory exclusivities akin to innovator pharmaceuticals. In most jurisdictions, commodity vitamin actives are:
- Off-patent on formulation and use, or protected only by legacy, narrow IP
- Commonly available via generics without paragraph IV frameworks (since there is no typical pioneer blockbuster patent stack)
What typically controls generic entry risk
For folic acid brands, generic entry is usually limited by:
- Manufacturing quality and GMP approvals
- Product availability and bioequivalence filings
- Labeling requirements for indication wording and strength
Patent-based delay is not the dominant factor versus cost and supply.
What is the Orange Book status of FOLVITE (folic acid) and how does that affect generic launch timing?
No Orange Book entry specific to a brand-labeled folic acid product is expected to create launch delay in the way innovator small molecules do, because folic acid products are typically not approved under pioneer exclusivity paradigms that generate Orange Book-rich patent estates.
Market entry timing for generic folic acid is therefore usually controlled by:
- ANDA readiness
- Commercial contracts and distribution
- Availability of branded strengths and packaging
(Orange Book “status” for generic vitamins tends to show limited or no meaningful patent barriers versus typical delayed-launch drugs.)
Which formulations are commercially important for folic acid brands like FOLVITE?
Strengths and dosage forms that drive substitution
Commercial switching usually concentrates on:
- Tablets (most common)
- Capsules (less common depending on country)
- Oral dosage strengths aligned with pregnancy and deficiency regimens
Formulation IP barriers
For folic acid, formulation patents rarely block entry at scale because:
- The active is stable and cheap
- Bioequivalence is straightforward for oral solid dosage forms
- Most “value” sits in packaging, brand trust, and channel placement
How strong is the patent estate for FOLVITE versus generic folic acid?
Patent estate reality for vitamins
Folic acid is an established nutrient. Most branded vitamin products do not maintain a broad, enforcement-ready patent estate that meaningfully affects market share.
As a result:
- Enforcement risk is generally low for generic folic acid
- Litigation is typically not a driver of supply or pricing
- Competitive dynamics follow generic penetration rates and procurement behavior
What generic entry risks exist for FOLVITE?
For folic acid brands, generic entry risks are mostly operational:
- GMP compliance and stability testing
- Regulatory labeling alignment
- Supply continuity
- Payer coverage and tender pricing
IP-driven generic launch risk (Paragraph IV) is usually not the primary risk category for commodity vitamin brands.
Commercial projection for FOLVITE: revenue outlook (2024–2035) and growth scenarios
Base-case framework
For a brand of folic acid, projections typically follow:
- Volume stability or mild growth tied to population need and pregnancy demographics
- Price compression due to generic competition
- Mix effects from higher-dose prescribing and combination products
Three-scenario projection (directional)
Because folic acid is a commodity vitamin, projections should be interpreted directionally rather than as brand-level exclusivity growth stories.
| Scenario |
Key assumptions |
Likely outcome for FOLVITE |
| Conservative |
Continued generic dominance, price pressure, flat supplementation adherence |
Revenue mostly flat in nominal terms with modest erosion |
| Base case |
Stable guideline adherence, steady pregnancy supplementation, procurement favors reliable suppliers |
Low-to-mid single digit growth in volume offsets partial price compression |
| Upside |
Higher compliance programs, expanded high-risk population coverage, reduced fortification substitution |
Modest nominal growth with improved share in select channels |
Main sensitivities
- National fortification and supplementation policy changes
- Maternal health program funding
- Tender and rebate structures affecting branded versus generic shelf placement
- Availability of combination products that can displace monotherapy tablets
Clinical development vs market development: what matters most for FOLVITE?
Why “trial pipelines” matter less
For folic acid brands, R&D is not usually linked to a patent life extension strategy. Commercial leverage comes from:
- Distribution relationships
- Reliability of supply
- Pharmacy formulary placement
- Packaging and strength availability
What new evidence could shift demand
Demand can move with:
- Updated maternal health guidance
- Safety communications influencing adherence
- Changes in prenatal care screening that drives supplement use
Key Takeaways
- FOLVITE is a brand of folic acid, a commodity active ingredient with limited brand-specific clinical trial momentum in modern registrational terms.
- Market demand is driven by pregnancy/periconception guidelines, folate deficiency management, and fortification policy rather than novel drug development.
- Patent-based exclusivity and Paragraph IV-style generic delay are typically not meaningful for folic acid brands; competition is dominated by generics and procurement economics.
- Revenue projections for FOLVITE are primarily volume-and-mix driven with continued price pressure.
FAQs
1) Is FOLVITE used for folate deficiency or pregnancy prevention?
Folic acid products like FOLVITE are used for folate deficiency and are standard in periconceptional/pregnancy prophylaxis per local guideline language.
2) Do clinical trials for folic acid lead to brand-level new indications for FOLVITE?
Most evidence accrues at the active-ingredient level; brand-specific registrational programs are uncommon.
3) Can generic folic acid products replace FOLVITE without clinical risk?
Substitution is generally controlled by dosing equivalence, formulation stability, and bioequivalence for oral solids; regulatory and procurement controls typically dominate.
4) How do folic acid fortification policies affect supplement brands like FOLVITE?
Fortification can reduce baseline supplement usage volume in the broader population but usually does not eliminate supplement recommendations for pregnancy planning/high-risk groups.
5) What are the biggest commercial threats to FOLVITE?
Price compression from generics, loss of formulary or tender position, and substitution by multivitamin combinations.
References
- World Health Organization. (2024). Recommendations on folic acid supplementation for pregnancy and public health. World Health Organization.
- FDA. (n.d.). Drugs@FDA and Orange Book resources for generic competition and exclusivity frameworks. U.S. Food and Drug Administration.
- NIH Office of Dietary Supplements. (n.d.). Folate Fact Sheet for Health Professionals. National Institutes of Health.
